Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVOEYE: AVT06 vs Eylea in neovascular (wet) age-related macular degeneration
jRCT2031220316Phase 3Completed
- Sponsor
- Alvotech
- Start
- Sep 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of AVT06 in exudative macular degeneration (2 arms), sponsored by Alvotech. Primary endpoint: Change from baseline to Week 8 in BCVA (ETDRS letter score). Started Sep 2022; status: completed.
02
Drugs
AVT06
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2031220316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220316.